CEO Matthew Klein was paid $23,266,326 in fiscal year 2025, ↑ up 214.0% from fiscal year 2024, the 94th percentile of its disclosed peer group (SEC filing 0001104659-26-045528 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$23,266,326 ↑ Matthew Klein total, FY2025 | 94th CEO pay percentile vs peers | — CEO-to-median pay ratio | 97.95% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
PTCT's next annual pay disclosure, estimated April 20, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Matthew Klein | $958,500 | $0 | $16,593,800 | $4,399,760 | $1,294,000 | $0 | $20,266 | $23,266,326 |
| Chief Executive Officer | ||||||||
| Eric Pauwels | 613,150 | 0 | 1,023,880 | 1,382,782 | 517,800 | 0 | 25,356 | 3,562,968 |
| Chief Business Officer | ||||||||
| Pierre Gravier | 579,167 | 0 | 1,047,150 | 1,414,209 | 488,600 | 0 | 21,660 | 3,550,786 |
| Chief Financial Officer | ||||||||
| Lee Golden | 574,667 | 0 | 930,800 | 1,257,074 | 482,800 | 0 | 23,838 | 3,269,179 |
| Executive Vice President and Chief Medical Officer | ||||||||
| Neil Almstead | 582,500 | 0 | 884,260 | 1,194,221 | 467,400 | 0 | 30,674 | 3,159,055 |
| Chief Technical Operations Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Matthew Klein | $23,266,326 | $7,410,765 | $8,937,025 | ↑ +15,855,561 |
| Eric Pauwels | 3,562,968 | 2,398,470 | 2,412,590 | ↑ +1,164,498 |
| Pierre Gravier | 3,550,786 | 2,227,654 | 2,734,475 | ↑ +1,323,132 |
| Lee Golden | 3,269,179 | 2,248,039 | 2,394,995 | ↑ +1,021,140 |
| Neil Almstead | 3,159,055 | 2,318,808 | 2,174,776 | ↑ +840,247 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read PTC THERAPEUTICS, INC.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper PTCT reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the PTC THERAPEUTICS, INC. Peer Teardown Report
$23,266,326 Matthew Klein total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 16, 2026 · Source: 0001104659-26-045528 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for PTCT
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order PTCT
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
The list of companies that name PTCT as a peer is temporarily unavailable — recheck shortly.
Get the PTC THERAPEUTICS, INC. Executive Compensation Report
$1,500
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Alethia Young | Independent Director | $475,905 |
| Allan Jacobson | Independent Director | $547,405 |
| David P. Southwell | Independent Director | $494,405 |
| Emma Reeve | Independent Director | $507,405 |
| Glenn D. Steele Jr | Independent Director | $477,405 |
| Jerome B. Zeldis | Independent Director | $463,905 |
| Jessica Chutter | Independent Director | — |
| Mary Smith | Independent Director | $479,405 |
| Michael Schmertzler | Chair of the Board | $896,310 |
| Stephanie S. Okey | Independent Director | $471,905 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Matthew B. Klein | Director | 2026-04-21 | D | 2,850 | $71 | $202,094 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-08 | D | 1,900 | 79 | 150,689 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-08 | A | 2,740 | 47 | 127,520 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-05-08 | — | 800 | — | — | 1 insider, 1 accrual row | ||
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-08 | D | 2,740 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-08 | D | 600 | 79 | 47,568 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-08 | D | 200 | 78 | 15,600 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-08 | A | 800 | 47 | 37,232 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-08 | D | 840 | 78 | 65,713 | Common | Form 4 ↗ |
| Matthew B. Klein | Director | 2026-05-13 | A | 12,500 | 0 | 0 | Common | Form 4 ↗ |
| Matthew B. Klein | Director | 2026-05-14 | D | 679 | 73 | 49,608 | Common | Form 4 ↗ |
| Matthew B. Klein | Director | 2026-05-14 | D | 2,100 | 73 | 153,468 | Common | Form 4 ↗ |
| Matthew B. Klein | Director | 2026-05-14 | D | 2,572 | 72 | 186,367 | Common | Form 4 ↗ |
| Matthew B. Klein | Director | 2026-05-14 | D | 7,221 | 73 | 527,711 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-15 | A | 2,812 | 26 | 72,240 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-15 | D | 2,356 | 72 | 169,820 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-15 | D | 2,812 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-15 | D | 456 | 73 | 33,138 | Common | Form 4 ↗ |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 2026-06-10 | D | 17,566 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 2026-06-10 | D | 3,711 | 75 | 278,325 | Common | Form 4 ↗ |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 2026-06-10 | D | 17,566 | 75 | 1,317,450 | Common | Form 4 ↗ |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 2026-06-10 | A | 17,566 | 18 | 316,364 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-06-17 | D | 1,703 | 79 | 133,686 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-06-17 | D | 1,850 | 79 | 146,594 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-06-17 | D | 309 | 79 | 24,488 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-06-17 | D | 6,600 | 79 | 518,100 | Common | Form 4 ↗ |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 2026-06-17 | D | 19,686 | 76 | 1,487,474 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-06-17 | A | 2,012 | 47 | 93,638 | Common | Form 4 ↗ |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 2026-06-17 | A | 19,686 | 26 | 505,733 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-06-17 | D | 2,012 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-06-17 | D | 8,510 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-06-17 | A | 8,510 | 47 | 396,055 | Common | Form 4 ↗ |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 2026-06-17 | D | 19,686 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-22 | D | 11,619 | 81 | 943,579 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-22 | A | 23,749 | 26 | 610,112 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-22 | D | 23,749 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-22 | D | 12,130 | 81 | 977,799 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-24 | — | 401 | — | — | 1 insider, 1 accrual row | ||
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-24 | D | 4,922 | 85 | 418,518 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-24 | D | 401 | 85 | 34,089 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-24 | A | 4,922 | 38 | 187,528 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-24 | A | 401 | 38 | 15,278 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-24 | D | 4,922 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-25 | — | 1,101 | — | — | 1 insider, 2 accrual rows | ||
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-25 | D | 19,859 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-25 | A | 19,859 | 38 | 756,628 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-25 | D | 582 | 85 | 49,610 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-25 | D | 8,522 | 85 | 726,586 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-25 | D | 419 | 86 | 36,197 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-25 | A | 1,001 | 38 | 38,138 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-25 | D | 100 | 87 | 8,700 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-25 | A | 100 | 39 | 3,942 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-25 | D | 11,337 | 87 | 980,764 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-26 | — | 412 | — | — | 1 insider, 1 accrual row | ||
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-26 | D | 7,718 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-26 | D | 7,718 | 85 | 658,037 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-26 | A | 7,718 | 38 | 294,056 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-26 | D | 412 | 85 | 35,115 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-26 | A | 412 | 38 | 15,697 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-06 | D | 426 | 85 | 36,329 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | D | 2,813 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | D | 2,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | D | 745 | 86 | 64,353 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-06 | D | 2,474 | 87 | 215,312 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-06 | D | 8,786 | 85 | 749,885 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-06 | D | 18,876 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-06 | — | 811 | — | — | 1 insider, 1 accrual row | ||
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-06 | D | 10,090 | 86 | 870,969 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-06 | A | 18,876 | 38 | 719,176 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | D | 601 | 86 | 51,914 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | D | 519 | 86 | 44,551 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-06 | D | 385 | 86 | 33,241 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | D | 313 | 83 | 26,010 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-06 | D | 2,474 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-06 | A | 2,474 | 39 | 97,525 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-06 | A | 811 | 38 | 30,899 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | D | 645 | 86 | 55,367 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | D | 1,036 | 84 | 87,449 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | D | 387 | 83 | 32,160 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | A | 2,813 | 47 | 130,917 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | D | 833 | 84 | 70,314 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | A | 2,266 | 39 | 89,326 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-07 | D | 24,613 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-07 | D | 9,288 | 89 | 830,719 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-07 | D | 11,369 | 89 | 1,012,182 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-07 | A | 24,613 | 39 | 970,244 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-07 | D | 3,956 | 87 | 344,845 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-09 | A | 2,464 | 47 | 114,675 | Common | Form 4 ↗ |
| Mary Smith | Director | 2026-07-09 | D | 5,834 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mary Smith | Director | 2026-07-09 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mary Smith | Director | 2026-07-09 | A | 5,834 | 43 | 250,570 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-09 | D | 2,464 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-09 | D | 2,464 | 90 | 222,376 | Common | Form 4 ↗ |
| Mary Smith | Director | 2026-07-09 | D | 5,834 | 90 | 525,060 | Common | Form 4 ↗ |
| Mary Smith | Director | 2026-07-09 | D | 10,000 | 90 | 900,000 | Common | Form 4 ↗ |
| Mary Smith | Director | 2026-07-09 | A | 10,000 | 43 | 429,500 | Common | Form 4 ↗ |
| Pierre Gravier | CHIEF FINANCIAL OFFICER | 2026-07-14 | D | 3,494 | 80 | 280,743 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-28 | — | 1,738 | — | — | 1 insider, 1 accrual row | ||
| Hege Elisabeth Sollie-Zetlmayer | Director | 2026-07-28 | A | 3,475 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hege Elisabeth Sollie-Zetlmayer | Director | 2026-07-28 | A | 2,000 | 0 | 0 | Common | Form 4 ↗ |
| Hege Elisabeth Sollie-Zetlmayer | Director | 2026-07-28 | A | 4,000 | 0 | 0 | Common | Form 4 ↗ |
| Matthew B. Klein | Director | 2026-08-04 | D | 10,292 | 69 | 705,722 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-08-17 | D | 1,844 | 72 | 133,487 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-08-17 | D | 2,813 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-08-17 | D | 969 | 73 | 70,640 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-08-17 | A | 2,813 | 26 | 72,266 | Common | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-08-19 | D | 7,165 | 74 | 527,846 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-08-19 | D | 5,335 | 73 | 388,708 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-08-20 | D | 691 | 73 | 50,388 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-08-20 | D | 2,390 | 72 | 171,793 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-08-20 | D | 9,419 | 71 | 666,677 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-08-26 | D | 6,874 | 73 | 500,015 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-08-26 | D | 5,626 | 73 | 411,711 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-08-27 | D | 11,890 | 72 | 850,730 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-08-27 | D | 610 | 72 | 44,054 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-09-09 | D | 572 | 69 | 39,279 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-09-09 | D | 9,428 | 68 | 639,124 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-09-10 | D | 10,000 | 67 | 673,400 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-09-16 | D | 7,006 | 67 | 471,854 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-09-16 | D | 2,994 | 67 | 199,341 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-09-17 | D | 376 | 68 | 25,737 | Common | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-09-17 | D | 9,624 | 68 | 652,796 | Common, indirect | Form 4 ↗ |
| Glenn D. Steele Jr | Director | 2026-09-30 | D | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Glenn D. Steele Jr | Director | 2026-09-30 | D | 12,000 | 65 | 781,920 | Common | Form 4 ↗ |
| Glenn D. Steele Jr | Director | 2026-09-30 | A | 12,000 | 11 | 134,760 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-10-05 | — | 1,638 | — | — | 1 insider, 1 accrual row | ||
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-10-05 | D | 1,638 | 64 | 104,881 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-10-05 | A | 1,638 | 39 | 64,570 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-10-06 | — | 435 | — | — | 1 insider, 1 accrual row | ||
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-10-06 | D | 435 | 64 | 27,910 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-10-06 | A | 435 | 39 | 17,148 | Common | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-10-07 | D | 53 | 64 | 3,389 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-10-07 | D | 2,447 | 63 | 155,091 | Common, indirect | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-10-09 | — | 192 | — | — | 1 insider, 1 accrual row | ||
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-10-09 | D | 192 | 64 | 12,338 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-10-09 | A | 192 | 39 | 7,569 | Common | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-10-14 | D | 382 | 60 | 22,973 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-10-14 | D | 2,118 | 60 | 126,063 | Common, indirect | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Matthew B. Klein | Director | 2026-04-21 | D | 2,850 | $71 | $202,094 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-08 | D | 1,900 | 79 | 150,689 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-08 | A | 2,740 | 47 | 127,520 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-08 | D | 800 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-08 | D | 2,740 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-08 | D | 600 | 79 | 47,568 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-08 | D | 200 | 78 | 15,600 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-08 | A | 800 | 47 | 37,232 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-08 | D | 840 | 78 | 65,713 | Common | Form 4 ↗ |
| Matthew B. Klein | Director | 2026-05-13 | A | 12,500 | 0 | 0 | Common | Form 4 ↗ |
| Matthew B. Klein | Director | 2026-05-14 | D | 679 | 73 | 49,608 | Common | Form 4 ↗ |
| Matthew B. Klein | Director | 2026-05-14 | D | 2,100 | 73 | 153,468 | Common | Form 4 ↗ |
| Matthew B. Klein | Director | 2026-05-14 | D | 2,572 | 72 | 186,367 | Common | Form 4 ↗ |
| Matthew B. Klein | Director | 2026-05-14 | D | 7,221 | 73 | 527,711 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-15 | A | 2,812 | 26 | 72,240 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-15 | D | 2,356 | 72 | 169,820 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-15 | D | 2,812 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-05-15 | D | 456 | 73 | 33,138 | Common | Form 4 ↗ |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 2026-06-10 | D | 17,566 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 2026-06-10 | D | 3,711 | 75 | 278,325 | Common | Form 4 ↗ |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 2026-06-10 | D | 17,566 | 75 | 1,317,450 | Common | Form 4 ↗ |
| Eric Pauwels | CHIEF BUSINESS OFFICER | 2026-06-10 | A | 17,566 | 18 | 316,364 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-06-17 | D | 1,703 | 79 | 133,686 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-06-17 | D | 1,850 | 79 | 146,594 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-06-17 | D | 309 | 79 | 24,488 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-06-17 | D | 6,600 | 79 | 518,100 | Common | Form 4 ↗ |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 2026-06-17 | D | 19,686 | 76 | 1,487,474 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-06-17 | A | 2,012 | 47 | 93,638 | Common | Form 4 ↗ |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 2026-06-17 | A | 19,686 | 26 | 505,733 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-06-17 | D | 2,012 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-06-17 | D | 8,510 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-06-17 | A | 8,510 | 47 | 396,055 | Common | Form 4 ↗ |
| Christine Marie Utter | SVP, CHIEF ACCOUNTING OFFICER | 2026-06-17 | D | 19,686 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-22 | D | 11,619 | 81 | 943,579 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-22 | A | 23,749 | 26 | 610,112 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-22 | D | 23,749 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-22 | D | 12,130 | 81 | 977,799 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-24 | D | 401 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-24 | D | 4,922 | 85 | 418,518 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-24 | D | 401 | 85 | 34,089 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-24 | A | 4,922 | 38 | 187,528 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-24 | A | 401 | 38 | 15,278 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-24 | D | 4,922 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-25 | D | 100 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-25 | D | 19,859 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-25 | D | 1,001 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-25 | A | 19,859 | 38 | 756,628 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-25 | D | 582 | 85 | 49,610 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-25 | D | 8,522 | 85 | 726,586 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-25 | D | 419 | 86 | 36,197 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-25 | A | 1,001 | 38 | 38,138 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-25 | D | 100 | 87 | 8,700 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-25 | A | 100 | 39 | 3,942 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-25 | D | 11,337 | 87 | 980,764 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-26 | D | 412 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-26 | D | 7,718 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-26 | D | 7,718 | 85 | 658,037 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-26 | A | 7,718 | 38 | 294,056 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-26 | D | 412 | 85 | 35,115 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-06-26 | A | 412 | 38 | 15,697 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-06 | D | 426 | 85 | 36,329 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | D | 2,813 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | D | 2,226 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | D | 745 | 86 | 64,353 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-06 | D | 2,474 | 87 | 215,312 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-06 | D | 8,786 | 85 | 749,885 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-06 | D | 18,876 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-06 | D | 811 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-06 | D | 10,090 | 86 | 870,969 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-06 | A | 18,876 | 38 | 719,176 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | D | 601 | 86 | 51,914 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | D | 519 | 86 | 44,551 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-06 | D | 385 | 86 | 33,241 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | D | 313 | 83 | 26,010 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-06 | D | 2,474 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-06 | A | 2,474 | 39 | 97,525 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-06 | A | 811 | 38 | 30,899 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | D | 645 | 86 | 55,367 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | D | 1,036 | 84 | 87,449 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | D | 387 | 83 | 32,160 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | A | 2,813 | 47 | 130,917 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | D | 833 | 84 | 70,314 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-07-06 | A | 2,266 | 39 | 89,326 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-07 | D | 24,613 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-07 | D | 9,288 | 89 | 830,719 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-07 | D | 11,369 | 89 | 1,012,182 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-07 | A | 24,613 | 39 | 970,244 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-07 | D | 3,956 | 87 | 344,845 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-09 | A | 2,464 | 47 | 114,675 | Common | Form 4 ↗ |
| Mary Smith | Director | 2026-07-09 | D | 5,834 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mary Smith | Director | 2026-07-09 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mary Smith | Director | 2026-07-09 | A | 5,834 | 43 | 250,570 | Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-09 | D | 2,464 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Neil Almstead | CHIEF TECHNICAL OPS OFFICER | 2026-07-09 | D | 2,464 | 90 | 222,376 | Common | Form 4 ↗ |
| Mary Smith | Director | 2026-07-09 | D | 5,834 | 90 | 525,060 | Common | Form 4 ↗ |
| Mary Smith | Director | 2026-07-09 | D | 10,000 | 90 | 900,000 | Common | Form 4 ↗ |
| Mary Smith | Director | 2026-07-09 | A | 10,000 | 43 | 429,500 | Common | Form 4 ↗ |
| Pierre Gravier | CHIEF FINANCIAL OFFICER | 2026-07-14 | D | 3,494 | 80 | 280,743 | Common | Form 4 ↗ |
| Hege Elisabeth Sollie-Zetlmayer | Director | 2026-07-28 | A | 1,738 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hege Elisabeth Sollie-Zetlmayer | Director | 2026-07-28 | A | 3,475 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hege Elisabeth Sollie-Zetlmayer | Director | 2026-07-28 | A | 2,000 | 0 | 0 | Common | Form 4 ↗ |
| Hege Elisabeth Sollie-Zetlmayer | Director | 2026-07-28 | A | 4,000 | 0 | 0 | Common | Form 4 ↗ |
| Matthew B. Klein | Director | 2026-08-04 | D | 10,292 | 69 | 705,722 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-08-17 | D | 1,844 | 72 | 133,487 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-08-17 | D | 2,813 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-08-17 | D | 969 | 73 | 70,640 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-08-17 | A | 2,813 | 26 | 72,266 | Common | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-08-19 | D | 7,165 | 74 | 527,846 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-08-19 | D | 5,335 | 73 | 388,708 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-08-20 | D | 691 | 73 | 50,388 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-08-20 | D | 2,390 | 72 | 171,793 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-08-20 | D | 9,419 | 71 | 666,677 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-08-26 | D | 6,874 | 73 | 500,015 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-08-26 | D | 5,626 | 73 | 411,711 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-08-27 | D | 11,890 | 72 | 850,730 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-08-27 | D | 610 | 72 | 44,054 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-09-09 | D | 572 | 69 | 39,279 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-09-09 | D | 9,428 | 68 | 639,124 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-09-10 | D | 10,000 | 67 | 673,400 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-09-16 | D | 7,006 | 67 | 471,854 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-09-16 | D | 2,994 | 67 | 199,341 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-09-17 | D | 376 | 68 | 25,737 | Common | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-09-17 | D | 9,624 | 68 | 652,796 | Common, indirect | Form 4 ↗ |
| Glenn D. Steele Jr | Director | 2026-09-30 | D | 12,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Glenn D. Steele Jr | Director | 2026-09-30 | D | 12,000 | 65 | 781,920 | Common | Form 4 ↗ |
| Glenn D. Steele Jr | Director | 2026-09-30 | A | 12,000 | 11 | 134,760 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-10-05 | D | 1,638 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-10-05 | D | 1,638 | 64 | 104,881 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-10-05 | A | 1,638 | 39 | 64,570 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-10-06 | D | 435 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-10-06 | D | 435 | 64 | 27,910 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-10-06 | A | 435 | 39 | 17,148 | Common | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-10-07 | D | 53 | 64 | 3,389 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-10-07 | D | 2,447 | 63 | 155,091 | Common, indirect | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-10-09 | D | 192 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-10-09 | D | 192 | 64 | 12,338 | Common | Form 4 ↗ |
| Mark Elliott Boulding | EXEC. VP AND CLO | 2026-10-09 | A | 192 | 39 | 7,569 | Common | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-10-14 | D | 382 | 60 | 22,973 | Common, indirect | Form 4 ↗ |
| Michael Schmertzler | Director | 2026-10-14 | D | 2,118 | 60 | 126,063 | Common, indirect | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Eric Pauwels | RSU | 2025-01-03 | — | — | 22,000 | — | $1,023,880 |
| Neil Almstead | RSU | 2025-01-03 | — | — | 19,000 | — | 884,260 |
| Matthew Klein | OPTION | 2025-01-03 | — | — | 175,000 | — | 4,399,760 |
| Neil Almstead | OPTION | 2025-01-03 | — | — | 47,500 | — | 1,194,221 |
| Pierre Gravier | RSU | 2025-01-03 | — | — | 22,500 | — | 1,047,150 |
| Lee Golden | RSU | 2025-01-03 | — | — | 20,000 | — | 930,800 |
| Matthew Klein | PSU | 2025-12-02 | — | 100,000 | — | 200,000 | 13,336,000 |
| Eric Pauwels | OPTION | 2025-01-03 | — | — | 55,000 | — | 1,382,782 |
| Lee Golden | OPTION | 2025-01-03 | — | — | 50,000 | — | 1,257,074 |
| Matthew Klein | RSU | 2025-01-03 | — | — | 70,000 | — | 3,257,800 |
| Pierre Gravier | OPTION | 2025-01-03 | — | — | 56,250 | — | 1,414,209 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Eric Pauwels | $1,023,880 | $0 | $1,382,782 | 0.0% |
| Neil Almstead | 884,260 | 0 | 1,194,221 | 0.0% |
| Matthew Klein | 3,257,800 | 13,336,000 | 4,399,760 | 63.5% |
| Pierre Gravier | 1,047,150 | 0 | 1,414,209 | 0.0% |
| Lee Golden | 930,800 | 0 | 1,257,074 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Eric Pauwels | RSU | 1,150 | — | $87,354 |
| Lee Golden | Option | 850 | 38.1 | — |
| Eric Pauwels | RSU | 9,000 | — | 683,640 |
| Lee Golden | RSU | 5,320 | — | 404,107 |
| Neil Almstead | RSU | 3,000 | — | 227,880 |
| Lee Golden | RSU | 20,000 | — | 1,519,200 |
| Pierre Gravier | RSU | 14,250 | — | 1,082,430 |
| Neil Almstead | RSU | 8,500 | — | 645,660 |
| Matthew Klein | RSU | 13,000 | — | 987,480 |
| Neil Almstead | RSU | 19,000 | — | 1,443,240 |
| Lee Golden | RSU | 2,039 | — | 154,882 |
| Matthew Klein | RSU | 5,250 | — | 398,790 |
| Lee Golden | RSU | 1,500 | — | 113,940 |
| Eric Pauwels | Option | 3,938 | 38.1 | — |
| Eric Pauwels | Option | 55,000 | 46.54 | — |
| Lee Golden | Option | 7,875 | 52.85 | — |
| Neil Almstead | Option | 3,375 | 38.1 | — |
| Neil Almstead | RSU | 14,250 | — | 1,082,430 |
| Pierre Gravier | RSU | 22,500 | — | 1,709,100 |
| Matthew Klein | RSU | 18,750 | — | 1,424,250 |
| Matthew Klein | Option | 24,375 | 52.96 | — |
| Lee Golden | Option | 3,563 | 39.42 | — |
| Matthew Klein | RSU | 70,000 | — | 5,317,200 |
| Matthew Klein | RSU | 50,000 | — | 3,798,000 |
| Pierre Gravier | RSU | 13,000 | — | 987,480 |
| Lee Golden | RSU | 4,200 | — | 319,032 |
| Matthew Klein | RSU | 52,500 | — | 3,987,900 |
| Eric Pauwels | RSU | 16,500 | — | 1,253,340 |
| Matthew Klein | PSU | 100,000 | — | 7,596,000 |
| Pierre Gravier | RSU | 1,550 | — | 117,738 |
| Lee Golden | Option | 625 | 38.1 | — |
| Matthew Klein | Option | 98,438 | 25.69 | — |
| Pierre Gravier | Option | 56,250 | 46.54 | — |
| Eric Pauwels | RSU | 22,000 | — | 1,671,120 |
| Lee Golden | RSU | 15,000 | — | 1,139,400 |
| Lee Golden | Option | 28,125 | 25.69 | — |
| Matthew Klein | PSU | 25,000 | — | 1,899,000 |
| Matthew Klein | PSU | 15,625 | — | 1,186,875 |
| Matthew Klein | Option | 3,282 | 38.1 | — |
| Matthew Klein | RSU | 7,813 | — | 593,475 |
| Neil Almstead | RSU | 3,600 | — | 273,456 |
| Pierre Gravier | Option | 26,719 | 25.69 | — |
| Eric Pauwels | Option | 30,938 | 25.69 | — |
| Neil Almstead | Option | 47,500 | 46.54 | — |
| Eric Pauwels | RSU | 4,200 | — | 319,032 |
| Lee Golden | RSU | 1,300 | — | 98,748 |
| Matthew Klein | Option | 175,000 | 46.54 | — |
| Neil Almstead | Option | 11,329 | 39.42 | — |
| Matthew Klein | Option | 20,313 | 39.42 | — |
| Pierre Gravier | Option | 28,438 | 39.82 | — |
| Eric Pauwels | Option | 14,063 | 39.42 | — |
| Lee Golden | Option | 50,000 | 46.54 | — |
| Neil Almstead | Option | 26,719 | 25.69 | — |
PTC's compensation program is designed to be competitive with peers and to motivate executives to achieve short-term and long-term strategy by placing a significant portion of compensation 'at risk'. The program aims to attract and retain qualified management while aligning the interests of executive officers with long-term stockholders through equity awards with time-based vesting schedules.
| CEO STI target (% of salary) | 80% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Frederic W. Cook & Co., Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-02 | 71,166,204 | 1,492,801 | 24,290 | 97.95% | Passed |
| 2025 | 2025-06-17 | 60,479,157 | 1,979,310 | 44,711 | 96.83% | Passed |
| 2024 | 2024-06-18 | 64,786,256 | 1,278,678 | 148,979 | 98.06% | Passed |
| 2023 | 2023-06-06 | 65,318,123 | 1,464,756 | 21,688 | 97.81% | Passed |
| 2022 | 2022-06-08 | 63,004,106 | 1,917,418 | 68,857 | 97.05% | Passed |
| 2021 | 2021-06-09 | 62,819,789 | 1,238,777 | 48,156 | 98.07% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-02 | 97.95%a |
| 2025 | 2025-06-17 | 96.83%b |
| 2024 | 2024-06-18 | 98.06%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Michael SchmertzlerIndependent · Board Chair · Nominating and Corporate Governance · Development · Compensation | $81,500 | $372,320 | $442,490 | — | $0 | $896,310 |
| Allan JacobsonIndependent · Development (Chair) | 50,000 | 186,160 | 221,245 | — | 90,000 | 547,405 |
| Allan Jacobson, Ph.DIndependent · Development (Chair) | 50,000 | 186,160 | 221,245 | — | 90,000 | 547,405 |
| Emma ReeveIndependent · Audit (Chair) · Compensation | 100,000 | 186,160 | 221,245 | — | 0 | 507,405 |
| David P. SouthwellIndependent · Audit · Compensation | 87,000 | 186,160 | 221,245 | — | 0 | 494,405 |
| Mary SmithIndependent · Audit · Compensation | 72,000 | 186,160 | 221,245 | — | 0 | 479,405 |
| Glenn D. Steele Jr., M.D., Ph.DIndependent · Compensation (Chair) · Development | 70,000 | 186,160 | 221,245 | — | 0 | 477,405 |
| Glenn D. Steele JrIndependent · Development · Compensation (Chair) | 70,000 | 186,160 | 221,245 | — | 0 | 477,405 |
| Alethia YoungIndependent · Audit · Nominating and Corporate Governance | 68,500 | 186,160 | 221,245 | — | 0 | 475,905 |
| Stephanie S. OkeyIndependent · Nominating and Corporate Governance (Chair) | 64,500 | 186,160 | 221,245 | — | 0 | 471,905 |
| Stephanie S. Okey, M.SIndependent · Nominating and Corporate Governance (Chair) | 64,500 | 186,160 | 221,245 | — | 0 | 471,905 |
| Jerome B. ZeldisIndependent · Nominating and Corporate Governance · Development | 56,500 | 186,160 | 221,245 | — | 0 | 463,905 |
| Jerome B. Zeldis, M.D., Ph.DIndependent · Nominating and Corporate Governance · Development | 56,500 | 186,160 | 221,245 | — | 0 | 463,905 |
| Jessica ChutterIndependent · Newly elected | 0 | 0 | 0 | — | 0 | 0 |
| Matthew B. KleinEmployee director · Development | — | — | — | — | — | 0 |
| Matthew B. Klein, M.D., M.S., F.A.C.SEmployee director · Development | — | — | — | — | — | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 14,500 |
| Stock ownership guideline | $150,000 |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $891,000 |
| Equity awards (grant-date value) | $2,606,240 |
| All other compensation | $180,000 |
| Total cost of the board | $3,677,240 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies PTC THERAPEUTICS, INC. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including PTC THERAPEUTICS, INC..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis, Inc. | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | PTC THERAPEUTICS, INC. | 2025 | Matthew Klein | 958,500 | 16,593,800 | 4,399,760 | 1,294,000 | 23,266,326 |
| 3 | Halozyme Therapeutics, Inc. | 2025 | Helen Torley | 1,000,000 | 19,350,145 | 1,650,014 | 1,147,500 | 23,166,223 |
| 4 | Madrigal Pharmaceuticals Corporation | 2025 | Bill Sibold | 918,531 | 12,297,850 | 4,537,146 | 1,438,814 | 19,206,341 |
| 5 | Jazz Pharmaceuticals plc | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 6 | Supernus Pharmaceuticals, Inc. | 2025 | Jack Khattar | 1,036,000 | 6,535,029 | 7,031,545 | 846,930 | 15,501,557 |
| 7 | Corcept Therapeutics Incorporated | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 8 | Insmed, Inc. | 2025 | William Lewis | 854,550 | 2,999,940 | 9,000,033 | 1,495,463 | 14,467,393 |
| 9 | Blueprint Medicines Corp. | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 10 | Ionis Pharmaceuticals, Inc. | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 11 | Pacira BioSciences, Inc. | 2025 | Frank Lee | 935,308 | 9,215,500 | 0 | 738,810 | 11,636,917 |
| 12 | Ultragenyx Pharmaceutical Inc. | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 13 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 14 | Axsome Therapeutics, Inc. | 2025 | Herriot Tabuteau | 835,000 | 5,533,554 | 2,833,237 | 876,750 | 10,283,492 |
| 15 | Intra-Cellular Therapies, Inc. | 2023 | Sharon Mates | 891,653 | 7,749,984 | 0 | 0 | 10,086,413 |
| 16 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 17 | ACADIA Pharmaceuticals Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 18 | Alkermes plc | 2025 | Richard Pops | 1,250,769 | 0 | 5,020,812 | 1,626,000 | 7,915,081 |
| 19 | Harmony Biosciences Holdings, Inc. | 2025 | Jeffrey Dayno | 743,600 | 1,976,520 | 4,599,000 | 558,000 | 7,899,535 |
| 20 | Sarepta Therapeutics, Inc. | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| PTC THERAPEUTICS, INC. | not disclosed | Option 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | Frederic W. Cook & Co., Inc. |
| ACADIA Pharmaceuticals Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Alkermes plc | 130% | PRSU 53 · RSU 24 · Option 23 | Yes — Relative Total Shareholder Return (TSR) | Alpine Rewards LLC |
| Amicus Therapeutics, Inc. | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Apellis Pharmaceuticals, Inc. | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Axsome Therapeutics, Inc. | 150% | RSU 33 · Options 33 · PSU 33 | No | Frederic W. Cook & Co., Inc. |
| Blueprint Medicines Corp. | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon |
| Corcept Therapeutics Incorporated | Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%% | Stock Options 100 | not disclosed | not disclosed |
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Halozyme Therapeutics, Inc. | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Harmony Biosciences Holdings, Inc. | 100% | not disclosed | not disclosed | Pay Governance |
| Insmed, Inc. | 175% | Options 75 · RSU 25 | No | Willis Towers Watson (WTW) |
| Intra-Cellular Therapies, Inc. | not disclosed | RSU 75 · PRSU 25 | Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology Index | Aon Consulting, Inc. |
| Ionis Pharmaceuticals, Inc. | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Jazz Pharmaceuticals plc | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Madrigal Pharmaceuticals Corporation | 195% | PSU 33 · RSU 33 · Options 33 | Yes — Relative TSR vs Nasdaq Biotechnology Index | Compensia |
| Pacira BioSciences, Inc. | 90% | RSU 80 · PSU 20 | No | Aon |
| Sarepta Therapeutics, Inc. | 100% | PSU 50 · Option 25 · RSU 25 | No | FW Cook |
| Supernus Pharmaceuticals, Inc. | not disclosed | not disclosed | No | Aon |
| Ultragenyx Pharmaceutical Inc. | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Matthew Klein | DEF 14A | 2026-04-20 | 0001104659-26-045528 | Section “Summary Compensation Table” · page 52. As printed: 23,266,326. Filing ↗ |
| 2 | Section 01, Eric Pauwels | DEF 14A | 2026-04-20 | 0001104659-26-045528 | Section “Summary Compensation Table” · page 52. As printed: 3,562,968. Filing ↗ |
| 3 | Section 01, Pierre Gravier | DEF 14A | 2026-04-20 | 0001104659-26-045528 | Section “Summary Compensation Table” · page 52. As printed: 3,550,786. Filing ↗ |
| 4 | Section 01, Lee Golden | DEF 14A | 2026-04-20 | 0001104659-26-045528 | Section “Summary Compensation Table” · page 52. As printed: 3,269,179. Filing ↗ |
| 5 | Section 01, Neil Almstead | DEF 14A | 2026-04-20 | 0001104659-26-045528 | Section “Summary Compensation Table” · page 52. As printed: 3,159,055. Filing ↗ |
| 6 | Section 03, Eric Pauwels RSU | DEF 14A | 1900-01-01 | 0001104659-26-045528 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 970536–970545 |
| 7 | Section 03, Neil Almstead RSU | DEF 14A | 1900-01-01 | 0001104659-26-045528 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 1013029–1013036 |
| 8 | Section 03, Matthew Klein OPTION | DEF 14A | 1900-01-01 | 0001104659-26-045528 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 914587–914596 |
| 9 | Section 03, Neil Almstead OPTION | DEF 14A | 1900-01-01 | 0001104659-26-045528 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 1005643–1005652 |
| 10 | Section 03, Pierre Gravier RSU | DEF 14A | 1900-01-01 | 0001104659-26-045528 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 949476–949485 |
| 11 | Section 03, Lee Golden RSU | DEF 14A | 1900-01-01 | 0001104659-26-045528 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 991551–991558 |
| 12 | Section 03, Matthew Klein PSU | DEF 14A | 1900-01-01 | 0001104659-26-045528 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 928832–928842 |
| 13 | Section 03, Eric Pauwels OPTION | DEF 14A | 1900-01-01 | 0001104659-26-045528 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 963099–963108 |
| 14 | Section 03, Lee Golden OPTION | DEF 14A | 1900-01-01 | 0001104659-26-045528 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 984678–984687 |
| 15 | Section 03, Matthew Klein RSU | DEF 14A | 1900-01-01 | 0001104659-26-045528 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 921452–921461 |
| 16 | Section 03, Pierre Gravier OPTION | DEF 14A | 1900-01-01 | 0001104659-26-045528 | Section “Grants of Plan-Based Awards in 2025” · grants of plan-based awards table. Filing ↗machine: span 942552–942561 |
| 17 | Section 08, Michael Schmertzler | DEF 14A | 2026-04-20 | 0001104659-26-045528 | Section “Director Compensation”. As printed: 896,310. Filing ↗machine: span 1908091–1908262 |
| 18 | Section 08, Allan Jacobson | DEF 14A | 2026-04-20 | 0001104659-26-045528 | Section “Director Compensation”. As printed: 547,405. Filing ↗machine: span 1916194–1916365 |
| 19 | Section 08, Allan Jacobson, Ph.D | DEF 14A | 2026-04-20 | 0001104659-26-045528 | Section “Director Compensation”. As printed: 547,405. Filing ↗machine: span 1916194–1916365 |
| 20 | Section 08, Emma Reeve | DEF 14A | 2026-04-20 | 0001104659-26-045528 | Section “Director Compensation”. As printed: 507,405. Filing ↗machine: span 1924070–1924241 |
| 21 | Section 08, David P. Southwell | DEF 14A | 2026-04-20 | 0001104659-26-045528 | Section “Director Compensation”. As printed: 494,405. Filing ↗machine: span 1932224–1932395 |
| 22 | Section 08, Mary Smith | DEF 14A | 2026-04-20 | 0001104659-26-045528 | Section “Director Compensation”. As printed: 479,405. Filing ↗machine: span 1928133–1928304 |
| 23 | Section 08, Glenn D. Steele Jr., M.D., Ph.D | DEF 14A | 2026-04-20 | 0001104659-26-045528 | Section “Director Compensation”. As printed: 477,405. Filing ↗machine: span 1936026–1936197 |
| 24 | Section 08, Glenn D. Steele Jr | DEF 14A | 2026-04-20 | 0001104659-26-045528 | Section “Director Compensation”. As printed: 477,405. Filing ↗machine: span 1936026–1936197 |
| 25 | Section 08, Alethia Young | DEF 14A | 2026-04-20 | 0001104659-26-045528 | Section “Director Compensation”. As printed: 475,905. Filing ↗machine: span 1940381–1940552 |
| 26 | Section 08, Stephanie S. Okey | DEF 14A | 2026-04-20 | 0001104659-26-045528 | Section “Director Compensation”. As printed: 471,905. Filing ↗machine: span 1919986–1920157 |
| 27 | Section 08, Stephanie S. Okey, M.S | DEF 14A | 2026-04-20 | 0001104659-26-045528 | Section “Director Compensation”. As printed: 471,905. Filing ↗machine: span 1919986–1920157 |
| 28 | Section 08, Jerome B. Zeldis | DEF 14A | 2026-04-20 | 0001104659-26-045528 | Section “Director Compensation”. As printed: 463,905. Filing ↗machine: span 1944176–1944347 |
| 29 | Section 08, Jerome B. Zeldis, M.D., Ph.D | DEF 14A | 2026-04-20 | 0001104659-26-045528 | Section “Director Compensation”. As printed: 463,905. Filing ↗machine: span 1944176–1944347 |
| 30 | Section 08, Jessica Chutter | DEF 14A | 2026-04-20 | 0001104659-26-045528 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 31 | Section 08, Matthew B. Klein | DEF 14A | 2026-04-20 | 0001104659-26-045528 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 32 | Section 08, Matthew B. Klein, M.D., M.S., F.A.C.S | DEF 14A | 2026-04-20 | 0001104659-26-045528 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 33 | Section 02, Matthew B. Klein 2026-04-21 | Form 4 | 2026-04-23 | 0001808968-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Mark Elliott Boulding 2026-05-08 | Form 4 | 2026-05-12 | 0001578852-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Mark Elliott Boulding 2026-05-08 | Form 4 | 2026-05-12 | 0001578852-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Mark Elliott Boulding 2026-05-08 | Form 4 | 2026-05-12 | 0001578852-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Mark Elliott Boulding 2026-05-08 | Form 4 | 2026-05-12 | 0001578852-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Mark Elliott Boulding 2026-05-08 | Form 4 | 2026-05-12 | 0001578852-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Mark Elliott Boulding 2026-05-08 | Form 4 | 2026-05-12 | 0001578852-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Mark Elliott Boulding 2026-05-08 | Form 4 | 2026-05-12 | 0001578852-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Mark Elliott Boulding 2026-05-08 | Form 4 | 2026-05-12 | 0001578852-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Matthew B. Klein 2026-05-13 | Form 4 | 2026-05-15 | 0001808968-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Matthew B. Klein 2026-05-14 | Form 4 | 2026-05-15 | 0001808968-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Matthew B. Klein 2026-05-14 | Form 4 | 2026-05-15 | 0001808968-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Matthew B. Klein 2026-05-14 | Form 4 | 2026-05-15 | 0001808968-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Matthew B. Klein 2026-05-14 | Form 4 | 2026-05-15 | 0001808968-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Mark Elliott Boulding 2026-05-15 | Form 4 | 2026-05-19 | 0001578852-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Mark Elliott Boulding 2026-05-15 | Form 4 | 2026-05-19 | 0001578852-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Mark Elliott Boulding 2026-05-15 | Form 4 | 2026-05-19 | 0001578852-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Mark Elliott Boulding 2026-05-15 | Form 4 | 2026-05-19 | 0001578852-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Eric Pauwels 2026-06-10 | Form 4 | 2026-06-12 | 0001323212-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Eric Pauwels 2026-06-10 | Form 4 | 2026-06-12 | 0001323212-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Eric Pauwels 2026-06-10 | Form 4 | 2026-06-12 | 0001323212-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Eric Pauwels 2026-06-10 | Form 4 | 2026-06-12 | 0001323212-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Mark Elliott Boulding 2026-06-17 | Form 4 | 2026-06-22 | 0001578852-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Mark Elliott Boulding 2026-06-17 | Form 4 | 2026-06-22 | 0001578852-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Mark Elliott Boulding 2026-06-17 | Form 4 | 2026-06-22 | 0001578852-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Mark Elliott Boulding 2026-06-17 | Form 4 | 2026-06-22 | 0001578852-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Christine Marie Utter 2026-06-17 | Form 4 | 2026-06-22 | 0001707685-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Mark Elliott Boulding 2026-06-17 | Form 4 | 2026-06-22 | 0001578852-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Christine Marie Utter 2026-06-17 | Form 4 | 2026-06-22 | 0001707685-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Mark Elliott Boulding 2026-06-17 | Form 4 | 2026-06-22 | 0001578852-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Mark Elliott Boulding 2026-06-17 | Form 4 | 2026-06-22 | 0001578852-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Mark Elliott Boulding 2026-06-17 | Form 4 | 2026-06-22 | 0001578852-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Christine Marie Utter 2026-06-17 | Form 4 | 2026-06-22 | 0001707685-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Neil Almstead 2026-06-22 | Form 4 | 2026-06-24 | 0001578850-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Neil Almstead 2026-06-22 | Form 4 | 2026-06-24 | 0001578850-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Neil Almstead 2026-06-22 | Form 4 | 2026-06-24 | 0001578850-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Neil Almstead 2026-06-22 | Form 4 | 2026-06-24 | 0001578850-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Neil Almstead 2026-06-24 | Form 4 | 2026-06-26 | 0001578850-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Neil Almstead 2026-06-24 | Form 4 | 2026-06-26 | 0001578850-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Neil Almstead 2026-06-24 | Form 4 | 2026-06-26 | 0001578850-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Neil Almstead 2026-06-24 | Form 4 | 2026-06-26 | 0001578850-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Neil Almstead 2026-06-24 | Form 4 | 2026-06-26 | 0001578850-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Neil Almstead 2026-06-24 | Form 4 | 2026-06-26 | 0001578850-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Neil Almstead 2026-06-25 | Form 4 | 2026-06-26 | 0001578850-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Neil Almstead 2026-06-25 | Form 4 | 2026-06-26 | 0001578850-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Neil Almstead 2026-06-25 | Form 4 | 2026-06-26 | 0001578850-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Neil Almstead 2026-06-25 | Form 4 | 2026-06-26 | 0001578850-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Neil Almstead 2026-06-25 | Form 4 | 2026-06-26 | 0001578850-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Neil Almstead 2026-06-25 | Form 4 | 2026-06-26 | 0001578850-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Neil Almstead 2026-06-25 | Form 4 | 2026-06-26 | 0001578850-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Neil Almstead 2026-06-25 | Form 4 | 2026-06-26 | 0001578850-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Neil Almstead 2026-06-25 | Form 4 | 2026-06-26 | 0001578850-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Neil Almstead 2026-06-25 | Form 4 | 2026-06-26 | 0001578850-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Neil Almstead 2026-06-25 | Form 4 | 2026-06-26 | 0001578850-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Neil Almstead 2026-06-26 | Form 4 | 2026-06-30 | 0001578850-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Neil Almstead 2026-06-26 | Form 4 | 2026-06-30 | 0001578850-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Neil Almstead 2026-06-26 | Form 4 | 2026-06-30 | 0001578850-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Neil Almstead 2026-06-26 | Form 4 | 2026-06-30 | 0001578850-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Neil Almstead 2026-06-26 | Form 4 | 2026-06-30 | 0001578850-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Neil Almstead 2026-06-26 | Form 4 | 2026-06-30 | 0001578850-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Neil Almstead 2026-07-06 | Form 4 | 2026-07-08 | 0001578850-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Mark Elliott Boulding 2026-07-06 | Form 4 | 2026-07-08 | 0001578852-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Mark Elliott Boulding 2026-07-06 | Form 4 | 2026-07-08 | 0001578852-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Mark Elliott Boulding 2026-07-06 | Form 4 | 2026-07-08 | 0001578852-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Neil Almstead 2026-07-06 | Form 4 | 2026-07-08 | 0001578850-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Neil Almstead 2026-07-06 | Form 4 | 2026-07-08 | 0001578850-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Neil Almstead 2026-07-06 | Form 4 | 2026-07-08 | 0001578850-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Neil Almstead 2026-07-06 | Form 4 | 2026-07-08 | 0001578850-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Neil Almstead 2026-07-06 | Form 4 | 2026-07-08 | 0001578850-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Neil Almstead 2026-07-06 | Form 4 | 2026-07-08 | 0001578850-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Mark Elliott Boulding 2026-07-06 | Form 4 | 2026-07-08 | 0001578852-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Mark Elliott Boulding 2026-07-06 | Form 4 | 2026-07-08 | 0001578852-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Neil Almstead 2026-07-06 | Form 4 | 2026-07-08 | 0001578850-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Mark Elliott Boulding 2026-07-06 | Form 4 | 2026-07-08 | 0001578852-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Neil Almstead 2026-07-06 | Form 4 | 2026-07-08 | 0001578850-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Neil Almstead 2026-07-06 | Form 4 | 2026-07-08 | 0001578850-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Neil Almstead 2026-07-06 | Form 4 | 2026-07-08 | 0001578850-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Mark Elliott Boulding 2026-07-06 | Form 4 | 2026-07-08 | 0001578852-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Mark Elliott Boulding 2026-07-06 | Form 4 | 2026-07-08 | 0001578852-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Mark Elliott Boulding 2026-07-06 | Form 4 | 2026-07-08 | 0001578852-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Mark Elliott Boulding 2026-07-06 | Form 4 | 2026-07-08 | 0001578852-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Mark Elliott Boulding 2026-07-06 | Form 4 | 2026-07-08 | 0001578852-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Mark Elliott Boulding 2026-07-06 | Form 4 | 2026-07-08 | 0001578852-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Neil Almstead 2026-07-07 | Form 4 | 2026-07-08 | 0001578850-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Neil Almstead 2026-07-07 | Form 4 | 2026-07-08 | 0001578850-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Neil Almstead 2026-07-07 | Form 4 | 2026-07-08 | 0001578850-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Neil Almstead 2026-07-07 | Form 4 | 2026-07-08 | 0001578850-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Neil Almstead 2026-07-07 | Form 4 | 2026-07-08 | 0001578850-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Neil Almstead 2026-07-09 | Form 4 | 2026-07-13 | 0001578850-26-000023 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Mary Smith 2026-07-09 | Form 4 | 2026-07-13 | 0001866044-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Mary Smith 2026-07-09 | Form 4 | 2026-07-13 | 0001866044-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, Mary Smith 2026-07-09 | Form 4 | 2026-07-13 | 0001866044-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, Neil Almstead 2026-07-09 | Form 4 | 2026-07-13 | 0001578850-26-000023 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, Neil Almstead 2026-07-09 | Form 4 | 2026-07-13 | 0001578850-26-000023 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, Mary Smith 2026-07-09 | Form 4 | 2026-07-13 | 0001866044-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, Mary Smith 2026-07-09 | Form 4 | 2026-07-13 | 0001866044-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, Mary Smith 2026-07-09 | Form 4 | 2026-07-13 | 0001866044-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, Pierre Gravier 2026-07-14 | Form 4 | 2026-07-16 | 0001984065-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, Hege Elisabeth Sollie-Zetlmayer 2026-07-28 | Form 4 | 2026-07-30 | 0002142653-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Hege Elisabeth Sollie-Zetlmayer 2026-07-28 | Form 4 | 2026-07-30 | 0002142653-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, Hege Elisabeth Sollie-Zetlmayer 2026-07-28 | Form 4 | 2026-07-30 | 0002142653-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, Hege Elisabeth Sollie-Zetlmayer 2026-07-28 | Form 4 | 2026-07-30 | 0002142653-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, Matthew B. Klein 2026-08-04 | Form 4 | 2026-08-06 | 0001808968-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Mark Elliott Boulding 2026-08-17 | Form 4 | 2026-08-19 | 0001578852-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Mark Elliott Boulding 2026-08-17 | Form 4 | 2026-08-19 | 0001578852-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, Mark Elliott Boulding 2026-08-17 | Form 4 | 2026-08-19 | 0001578852-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, Mark Elliott Boulding 2026-08-17 | Form 4 | 2026-08-19 | 0001578852-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, Michael Schmertzler 2026-08-19 | Form 4 | 2026-08-21 | 0001288952-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, Michael Schmertzler 2026-08-19 | Form 4 | 2026-08-21 | 0001288952-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, Michael Schmertzler 2026-08-20 | Form 4 | 2026-08-21 | 0001288952-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, Michael Schmertzler 2026-08-20 | Form 4 | 2026-08-21 | 0001288952-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 02, Michael Schmertzler 2026-08-20 | Form 4 | 2026-08-21 | 0001288952-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 145 | Section 02, Michael Schmertzler 2026-08-26 | Form 4 | 2026-08-28 | 0001288952-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 146 | Section 02, Michael Schmertzler 2026-08-26 | Form 4 | 2026-08-28 | 0001288952-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 147 | Section 02, Michael Schmertzler 2026-08-27 | Form 4 | 2026-08-28 | 0001288952-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 148 | Section 02, Michael Schmertzler 2026-08-27 | Form 4 | 2026-08-28 | 0001288952-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 149 | Section 02, Michael Schmertzler 2026-09-09 | Form 4 | 2026-09-11 | 0001288952-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 150 | Section 02, Michael Schmertzler 2026-09-09 | Form 4 | 2026-09-11 | 0001288952-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 151 | Section 02, Michael Schmertzler 2026-09-10 | Form 4 | 2026-09-11 | 0001288952-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 152 | Section 02, Michael Schmertzler 2026-09-16 | Form 4 | 2026-09-18 | 0001288952-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 153 | Section 02, Michael Schmertzler 2026-09-16 | Form 4 | 2026-09-18 | 0001288952-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 154 | Section 02, Michael Schmertzler 2026-09-17 | Form 4 | 2026-09-18 | 0001288952-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 155 | Section 02, Michael Schmertzler 2026-09-17 | Form 4 | 2026-09-18 | 0001288952-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 156 | Section 02, Glenn D. Steele Jr 2026-09-30 | Form 4 | 2026-10-02 | 0001269131-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 157 | Section 02, Glenn D. Steele Jr 2026-09-30 | Form 4 | 2026-10-02 | 0001269131-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 158 | Section 02, Glenn D. Steele Jr 2026-09-30 | Form 4 | 2026-10-02 | 0001269131-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 159 | Section 02, Mark Elliott Boulding 2026-10-05 | Form 4 | 2026-10-07 | 0001578852-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 160 | Section 02, Mark Elliott Boulding 2026-10-05 | Form 4 | 2026-10-07 | 0001578852-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 161 | Section 02, Mark Elliott Boulding 2026-10-05 | Form 4 | 2026-10-07 | 0001578852-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 162 | Section 02, Mark Elliott Boulding 2026-10-06 | Form 4 | 2026-10-07 | 0001578852-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 163 | Section 02, Mark Elliott Boulding 2026-10-06 | Form 4 | 2026-10-07 | 0001578852-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 164 | Section 02, Mark Elliott Boulding 2026-10-06 | Form 4 | 2026-10-07 | 0001578852-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 165 | Section 02, Michael Schmertzler 2026-10-07 | Form 4 | 2026-10-09 | 0001288952-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 166 | Section 02, Michael Schmertzler 2026-10-07 | Form 4 | 2026-10-09 | 0001288952-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 167 | Section 02, Mark Elliott Boulding 2026-10-09 | Form 4 | 2026-10-13 | 0001578852-26-000026 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 168 | Section 02, Mark Elliott Boulding 2026-10-09 | Form 4 | 2026-10-13 | 0001578852-26-000026 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 169 | Section 02, Mark Elliott Boulding 2026-10-09 | Form 4 | 2026-10-13 | 0001578852-26-000026 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 170 | Section 02, Michael Schmertzler 2026-10-14 | Form 4 | 2026-10-16 | 0001288952-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 171 | Section 02, Michael Schmertzler 2026-10-14 | Form 4 | 2026-10-16 | 0001288952-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 172 | Section 06, 2026 vote | Form 8-K | 2026-06-05 | 0001104659-26-071040 | Item 5.07 · say-on-pay result. As reported: 97.95% (votes for as printed: 71,166,204). Filing ↗ |
| 173 | Section 06, 2025 vote | Form 8-K | 2025-06-17 | 0001558370-25-008694 | Item 5.07 · say-on-pay result. As reported: 96.83% (votes for as printed: 60,479,157). Filing ↗ |
| 174 | Section 06, 2024 vote | Form 8-K | 2024-06-20 | 0001558370-24-009313 | Item 5.07 · say-on-pay result. As reported: 98.06% (votes for as printed: 64,786,256). Filing ↗ |
| 175 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 176 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 177 | Section 09b board cost (computed) | Computed | — | — | Cash 891,000 + equity 2,606,240 + all other 180,000 = 3,677,240, summed across the director compensation table rows.machine: formula: Σ = 3,677,240 |
| 178 | Exelixis, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0000939767-26-000046 | CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526 |
| 179 | PTC THERAPEUTICS, INC. (subject), Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045528 | CEO total compensation as printed in PTC THERAPEUTICS, INC.'s own proxy. As printed: 23,266,326. Filing ↗ |
| 180 | Halozyme Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-03-23 | 0001159036-26-000041 | CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292 |
| 181 | Madrigal Pharmaceuticals Corporation, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001308179-26-000352 | CEO total compensation as printed in Madrigal Pharmaceuticals Corporation's own proxy. As printed: 19,206,341. Filing ↗machine: r2 · c24 · span 791942–791952 |
| 182 | Jazz Pharmaceuticals plc, Section 10b CEO total | DEF 14A | 2026-06-08 | 0001232524-26-000029 | CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379 |
| 183 | Supernus Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-30 | 0001104659-26-053111 | CEO total compensation as printed in Supernus Pharmaceuticals, Inc.'s own proxy. As printed: 15,501,557. Filing ↗machine: r1 · c41 · span 430594–430604 |
| 184 | Corcept Therapeutics Incorporated, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001628280-26-025735 | CEO total compensation as printed in Corcept Therapeutics Incorporated's own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514 |
| 185 | Insmed, Inc., Section 10b CEO total | DEF 14A | 2026-04-01 | 0001104506-26-000022 | CEO total compensation as printed in Insmed, Inc.'s own proxy. As printed: 14,467,393. Filing ↗machine: r4 · c51 · span 912553–912563 |
| 186 | Blueprint Medicines Corp., Section 10b CEO total | DEF 14A | 2025-04-24 | 0001558370-25-005415 | CEO total compensation as printed in Blueprint Medicines Corp.'s own proxy. As printed: 13,477,004. Filing ↗machine: span 1101152–1101162 |
| 187 | Ionis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. Filing ↗ |
| 188 | Pacira BioSciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050353 | CEO total compensation as printed in Pacira BioSciences, Inc.'s own proxy. As printed: 11,636,917. Filing ↗machine: t136 · r1 · c47 · span 2412158–2412168 |
| 189 | Ultragenyx Pharmaceutical Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0001308179-26-000174 | CEO total compensation as printed in Ultragenyx Pharmaceutical Inc.'s own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007 |
| 190 | Apellis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2025-04-23 | 0000950170-25-056966 | CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565 |
| 191 | Axsome Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177610 | CEO total compensation as printed in Axsome Therapeutics, Inc.'s own proxy. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246 |
| 192 | Intra-Cellular Therapies, Inc., Section 10b CEO total | DEF 14A | 2024-04-29 | 0001628280-24-018986 | CEO total compensation as printed in Intra-Cellular Therapies, Inc.'s own proxy. As printed: 10,086,413. Filing ↗machine: r2 · c39 · span 440593–440603 |
| 193 | Amicus Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-24 | 0001140361-25-015479 | CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136 |
| 194 | ACADIA Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in ACADIA Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. Filing ↗ |
| 195 | Alkermes plc, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001193125-26-143977 | CEO total compensation as printed in Alkermes plc's own proxy. As printed: 7,915,081. Filing ↗machine: r3 · c33 · span 2508258–2508267 |
| 196 | Harmony Biosciences Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-03 | 0001104659-26-039449 | CEO total compensation as printed in Harmony Biosciences Holdings, Inc.'s own proxy. As printed: 7,899,535. Filing ↗machine: t108 · r5 · c16 · span 580355–580364 |
| 197 | Sarepta Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177247 | CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. Filing ↗machine: span 1454395–1454404 |
| 198 | Section 10a, Exelixis, Inc. reciprocity | DEF 14A | — | 0000939767-26-000046 | Exelixis, Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 199 | Section 10a, Jazz Pharmaceuticals plc reciprocity | DEF 14A | — | 0001232524-26-000029 | Jazz Pharmaceuticals plc's most recent proxy was read; its disclosed peer group does not include PTC THERAPEUTICS, INC.. Filing ↗ |
| 200 | Section 10a, Supernus Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001104659-26-053111 | Supernus Pharmaceuticals, Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 201 | Section 10a, Insmed, Inc. reciprocity | DEF 14A | — | 0001104506-26-000022 | Insmed, Inc.'s most recent proxy was read; its disclosed peer group does not include PTC THERAPEUTICS, INC.. Filing ↗ |
| 202 | Section 10a, Axsome Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-177610 | Axsome Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include PTC THERAPEUTICS, INC.. Filing ↗ |
| 203 | Section 10a, Madrigal Pharmaceuticals Corporation reciprocity | DEF 14A | — | 0001308179-26-000352 | Madrigal Pharmaceuticals Corporation's most recent proxy was read; its disclosed peer group does not include PTC THERAPEUTICS, INC.. Filing ↗ |
| 204 | Section 10a, Sarepta Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-177247 | Sarepta Therapeutics, Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 205 | Section 10a, Halozyme Therapeutics, Inc. reciprocity | DEF 14A | — | 0001159036-26-000041 | Halozyme Therapeutics, Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 206 | Section 10a, ACADIA Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001193125-26-174163 | ACADIA Pharmaceuticals Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 207 | Section 10a, Ionis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals, Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 208 | Section 10a, Ultragenyx Pharmaceutical Inc. reciprocity | DEF 14A | — | 0001308179-26-000174 | Ultragenyx Pharmaceutical Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 209 | Section 10a, Blueprint Medicines Corp. reciprocity | DEF 14A | — | 0001558370-25-005415 | Blueprint Medicines Corp. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 210 | Section 10a, Harmony Biosciences Holdings, Inc. reciprocity | DEF 14A | — | 0001104659-26-039449 | Harmony Biosciences Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include PTC THERAPEUTICS, INC.. Filing ↗ |
| 211 | Section 10a, Pacira BioSciences, Inc. reciprocity | DEF 14A | — | 0001104659-26-050353 | Pacira BioSciences, Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 212 | Section 10a, Apellis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0000950170-25-056966 | Apellis Pharmaceuticals, Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 213 | Section 10a, Amicus Therapeutics, Inc. reciprocity | DEF 14A | — | 0001140361-25-015479 | Amicus Therapeutics, Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 214 | Section 10a, Intra-Cellular Therapies, Inc. reciprocity | DEF 14A | — | 0001628280-24-018986 | Intra-Cellular Therapies, Inc. names PTC THERAPEUTICS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the PTC THERAPEUTICS, INC. Executive Compensation Report
$1,500